
2020 continues to be a breakthrough year for M2D2 Resident Company Versatope Therapeutics, Inc. On September 9, they announced that they had been awarded a Phase 1 Small Business and Innovation Award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). This grant will support their development of a novel vaccine for the prevention and possible treatment for Clostridioides difficile, also known as C. diff.
Continue reading